NCT03289962 is a Phase 1 clinical trial of Autogene cevumeran in Melanoma, sponsored by Genentech, Inc..

Who is sponsoring NCT03289962?

NCT03289962 is sponsored by Genentech, Inc..

What drugs are being tested in NCT03289962?

Interventions in NCT03289962: Autogene cevumeran, Atezolizumab.

What condition does NCT03289962 study?

NCT03289962 studies Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Renal Cancer, Head and Neck Cancer, Other Solid Cancers.

Is NCT03289962 still recruiting?

NCT03289962 is currently completed. Last updated 4 July 2025.

Last reviewed 2025-07-04 · How we verify

NCT03289962

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Completed Phase 1 Last updated 4 July 2025

What this trial tests

Phase 1 trial testing Autogene cevumeran in Melanoma in 272 participants. Completed in 1 July 2025.

Timeline

21 December 2017

Primary endpoint
1 July 2025

1 July 2025

Quick facts

Lead sponsor	Genentech, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	272
Start date	21 December 2017
Primary completion	1 July 2025
Estimated completion	1 July 2025
Sites	26 locations across Netherlands, Belgium, Sweden, United Kingdom, Germany, Canada, United States, Spain

Drugs / interventions tested

Autogene cevumeran — full drug profile →
Atezolizumab (atezolizumab) — full drug profile →

Conditions studied

Melanoma — all drugs for Melanoma →
Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →
Bladder Cancer — all drugs for Bladder Cancer →
Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

Genentech, Inc. — full company profile →

Who can join

18 and older, any sex, with Melanoma or Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 \[anti-PD-L1\] antibody).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities.
Ho WJ, Jaffee EM, Zheng L. · · 2020 · cited 963× · PMID 32398706 · DOI 10.1038/s41571-020-0363-5
Towards personalized, tumour-specific, therapeutic vaccines for cancer.
Hu Z, Ott PA, Wu CJ. · · 2018 · cited 772× · PMID 29226910 · DOI 10.1038/nri.2017.131
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.
Kowalski PS, Rudra A, Miao L, Anderson DG. · · 2019 · cited 749× · PMID 30846391 · DOI 10.1016/j.ymthe.2019.02.012
Neoantigens: promising targets for cancer therapy.
Xie N, Shen G, Gao W, Huang Z, et al · · 2023 · cited 713× · PMID 36604431 · DOI 10.1038/s41392-022-01270-x
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines.
Blass E, Ott PA. · · 2021 · cited 700× · PMID 33473220 · DOI 10.1038/s41571-020-00460-2
A review of cancer immunotherapy: from the past, to the present, to the future.
Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, et al · · 2020 · cited 652× · PMID 32368178 · DOI 10.3747/co.27.5223
mRNA vaccine for cancer immunotherapy.
Miao L, Zhang Y, Huang L. · · 2021 · cited 640× · PMID 33632261 · DOI 10.1186/s12943-021-01335-5
Turning cold tumors into hot tumors by improving T-cell infiltration.
Liu YT, Sun ZJ. · · 2021 · cited 560× · PMID 33859752 · DOI 10.7150/thno.58390

Verify or expand the search:

Other trials of Autogene cevumeran

Trials testing the same drug.

NCT05968326 — A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX A · Phase 2 · recruiting
NCT03815058 — A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus P · Phase 2 · completed

Other recruiting trials for Melanoma

Currently open trials in the same condition.

NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT · NA · recruiting
NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve · NA · recruiting

Other Genentech, Inc. trials

Trials by the same sponsor.

NCT06984341 — A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in P · Phase 1 · recruiting
NCT07448038 — A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vas · Phase 2 · recruiting
NCT07425522 — A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With D · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting
NCT07214662 — A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Gire · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03289962 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Genentech, Inc.
Last refreshed: 4 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03289962.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing